- Home
- LGCL vs BOLD Comparison
LGCL vs BOLD Comparison
Compare LGCL & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCL
- BOLD
- Stock Information
- Founded
- LGCL 2009
- BOLD 2018
- Country
- LGCL China
- BOLD United States
- Employees
- LGCL N/A
- BOLD N/A
- Industry
- LGCL
- BOLD
- Sector
- LGCL
- BOLD
- Exchange
- LGCL NYSE
- BOLD Nasdaq
- Market Cap
- LGCL 39.7M
- BOLD 30.3M
- IPO Year
- LGCL 2024
- BOLD 2024
- Fundamental
- Price
- LGCL $0.51
- BOLD $1.10
- Analyst Decision
- LGCL
- BOLD Hold
- Analyst Count
- LGCL 0
- BOLD 2
- Target Price
- LGCL N/A
- BOLD $3.00
- AVG Volume (30 Days)
- LGCL 69.4K
- BOLD 78.5K
- Earning Date
- LGCL 01-01-0001
- BOLD 05-09-2025
- Dividend Yield
- LGCL N/A
- BOLD N/A
- EPS Growth
- LGCL N/A
- BOLD N/A
- EPS
- LGCL 0.07
- BOLD N/A
- Revenue
- LGCL $145,690,427.00
- BOLD N/A
- Revenue This Year
- LGCL N/A
- BOLD N/A
- Revenue Next Year
- LGCL N/A
- BOLD N/A
- P/E Ratio
- LGCL $7.45
- BOLD N/A
- Revenue Growth
- LGCL N/A
- BOLD N/A
- 52 Week Low
- LGCL $0.28
- BOLD $1.06
- 52 Week High
- LGCL $3.31
- BOLD $10.13
- Technical
- Relative Strength Index (RSI)
- LGCL N/A
- BOLD N/A
- Support Level
- LGCL N/A
- BOLD N/A
- Resistance Level
- LGCL N/A
- BOLD N/A
- Average True Range (ATR)
- LGCL 0.00
- BOLD 0.00
- MACD
- LGCL 0.00
- BOLD 0.00
- Stochastic Oscillator
- LGCL 0.00
- BOLD 0.00
About LGCL LUCAS GC LIMITED
Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China. Its business segments consist of recruitment services, outsourcing services, and other services, which include information technology services and training services.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.